Rx License-Rx

TAB-1493

Epithelial Cell Line Expressing a Cystic Fibrosis Phenotype

Cystic fibrosis (CF) is a common genetic disease that affects the entire body, producing thick, sticky mucus that clogs the lungs, pancreas, and other organs. It is the most common fatal genetic disease in the United States, and is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR). Researchers at NIEHS have developed a cell line, CF/T43, which was produced by infection of airway epithelial cells isolated from CF patients with an SV40T retrovirus. CF/T43 cells maintain the abnormal ion transport characteristics of CF while having proliferation capability beyond that of a primary epithelial cell culture. Key features of the CF/T43 cell line include the formation of functional tight junctions, reduced apical membrane chloride conductance, and activation of apical chloride channels by calcium ionophores but not by cAMP-dependent agonists. This cell line may be used for elucidation of the mechanisms of...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Inflammation

Indication: Pulmonology

Modality: Small Molecule

Focus tags: Inflammation, Infectious Disease

Technology tags: Small Molecule, Diagnostic / Biomarker, Biomanufacturing

Mechanism:

Development stage: Early / Discovery

Patent status: Expired

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Inflammation. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be early / discovery and is associated with National Institutes of Health. The practical first use case is Pulmonology. Public description: Cystic fibrosis (CF) is a common genetic disease that affects the entire body, producing thick, sticky mucus that clogs the lungs, pancreas, and other organs. It is the most common fatal genetic disease in the United States, and is caused.

What is exciting

Early enough to shape the whole strategy: Because the asset is still early, a licensee can choose the best indication, data package, CRO path, and partnering story before heavy spend.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Negatives / diligence concerns

Very early technical risk: The asset likely still needs independent replication, translational validation, and a clear go/no-go experiment before a serious license fee is justified.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Inflammation wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets GSK — Vaccines and anti-infective infrastructure. Pfizer — Hospital, anti-infective, and vaccine commercial reach. Johnson & Johnson — Pathogen-focused development and global health channels.

Development Strategy to Increase PoS

First indication: Pulmonology

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Best next experiment: Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.